Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

NCT06706284 on ClinicalTrials.gov · last registry update 2026-10-05

Recruiting now, toward 50 participants. Due to report 1 September 2028, alongside 23 other tracked readouts that quarter. Primary outcome, as filed: Glucose tolerance. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Marzieh Salehi
Sponsor type: Other
Enrollment: 50
Started: 2025-04-11
Primary completion: 2028-09-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Glucose tolerance

Conditions studied

Spinal Cord Injuries · Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.